ResoTher Pharma
ResoTher Pharma is a clinical stage biotechnology company located in Copenhagen, Denmark, focused on discovering and developing peptide-based drugs as resolution therapy for diseases where inflammation plays a key pathological role. The company aims to improve patient outcomes by creating novel medicines that benefit patients in need, particularly targeting inflammation via resolution therapy to treat cardiovascular diseases. The company actively advances its clinical programs, including initiating dosing in Phase 2a trials and exploring innovative therapies for cardiovascular conditions.
Industries
Nr. of Employees
small (1-50)
ResoTher Pharma
Dronninggaards Alle 136, 2840 Holte, Denmark
Patents
Products
Lead peptide therapeutic candidate for myocardial infarction
A peptide-based pro-resolving therapeutic candidate developed to reduce neutrophil-driven inflammation and support tissue recovery after myocardial infarction; supported by preclinical IND-enabling studies and progressed into early clinical testing (Phase I/Phase 2a).
Lead peptide therapeutic candidate for myocardial infarction
A peptide-based pro-resolving therapeutic candidate developed to reduce neutrophil-driven inflammation and support tissue recovery after myocardial infarction; supported by preclinical IND-enabling studies and progressed into early clinical testing (Phase I/Phase 2a).
Services
Discovery-stage pharmacology, DMPK and toxicology studies to support candidate nomination and regulatory filings for first-in-human trials.
Design and conduct of Phase I dose-escalation studies and progression into Phase 2a clinical trials with integrated PK, safety and biomarker endpoints, including intravenous administration.
Discovery-stage pharmacology, DMPK and toxicology studies to support candidate nomination and regulatory filings for first-in-human trials.
Design and conduct of Phase I dose-escalation studies and progression into Phase 2a clinical trials with integrated PK, safety and biomarker endpoints, including intravenous administration.
Expertise Areas
- Peptide therapeutics and pro-resolving immunomodulation
- Cardiovascular drug development (myocardial infarction)
- Early-phase clinical trial management and operations
- Preclinical pharmacology, DMPK and toxicology
Key Technologies
- Peptide drug design and optimization
- Intravenous infusion administration and dose-escalation protocols
- Pharmacokinetics (PK) and DMPK analysis
- Clinical biomarker measurement and analysis
News & Updates
ResoTher Pharma is pleased to announce that the first patient has been dosed in its Phase 2a clinical trial for RTP-026, a lead peptide drug candidate, to evaluate safety, tolerability, and pharmacokinetics in humans.
A biography published in Life Sciences Review highlights ResoTher Pharma's efforts in improving cardiovascular outcomes.
ResoTher Pharma announced receiving a €2.5 million grant from the European Innovation Council to support a phase 2a clinical study of their lead candidate RTP-026 for myocardial infarction.
ResoTher Pharma was profiled by the Danish biotech publication MedWatch.
ResoTher Pharma was nominated and awarded the prestigious Merck Advance Biotech Grant.
ResoTher Pharma was pleased to announce winning the Innobooster award.
ResoTher Pharma is pleased to announce that the first patient has been dosed in its Phase 2a clinical trial for RTP-026, a lead peptide drug candidate, to evaluate safety, tolerability, and pharmacokinetics in humans.
A biography published in Life Sciences Review highlights ResoTher Pharma's efforts in improving cardiovascular outcomes.
ResoTher Pharma announced receiving a €2.5 million grant from the European Innovation Council to support a phase 2a clinical study of their lead candidate RTP-026 for myocardial infarction.
ResoTher Pharma was profiled by the Danish biotech publication MedWatch.
ResoTher Pharma was nominated and awarded the prestigious Merck Advance Biotech Grant.
ResoTher Pharma was pleased to announce winning the Innobooster award.